Buy Amgen After the Novartis-Led Pullback - High-Quality Cash Flow at a Discount
Amgen shares dropped after Novartis reported a Phase III miss for pelacarsen on 09/07/2026, creating an opportunity to buy a high-quality cash flow generator at reasonable multiples. With $10.2B of free cash flow, a $211.5B market cap, a 2.52% yield and technicals showing oversold conditions, we rate AMGN a buy for a swing trade into renewed clarit…